ArticleHepatic medicine : evidence and research2021
Hepatitis and HIV Co-infection at University of Gondar Specialized Referral Hospital: Northwest Ethiopia.
Article in Hepatic medicine : evidence and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.
- Pooled it
- Prevalence of hepatitis B virus infection and its associated factors in Ethiopia: a recent systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Protocol for a Pilot Quasi-Experimental Study on the Effect of Patient-Centered Education on HIV Virological Outcomes Among Adult People Live With HIV-HBV Co-Infection in North-West Ethiopia: Protocol for a Pilot Quasi-Experimental Study.Health science reports · 2026Article
- Seroprevalence and viremia of hepatitis C virus among HIV-infected patients on ART with unsuppressed HIV viral load in Ethiopia.AIDS research and therapy · 2026Article
- HIV and HCV co-infection in patients on antiretroviral therapy: a case study of selected health facilities in Ilorin, Nigeria.BMC infectious diseases · 2026Article
- HIV/AIDS and HBV co-infection with optimal control strategies and cost-effectiveness analyses using integer order model.Scientific reports · 2025Article
- A dynamical optimal control theory and cost-effectiveness analyses of the HBV and HIV/AIDS co-infection model.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundViral infections are the most common diseases. Of them, human immunodeficiency virus (HIV), hepatitis B viruses (HBV), and hepatitis C viruses (HCV) are common. When HBV or HCV becomes co-morbid with HIV, they lead to severe forms of a disease and rapid death.
objectiveThis study aimed to determine the seroprevalence and associated factors of HBV and HCV among HIV-positive study participants.
methodsA cross-sectional study was conducted among 81 individuals, and a non-randomized purposive sampling technique was used. From each study participant, sociodemographic and clinical data were gathered by using a pretested questionnaire and data collection sheet, respectively. Further, a venous blood sample was collected for viral load count, and HBV and HCV determination. To keep the quality of test results, commercially prepared quality control samples were used. The data were entered to EPI-Info version 7 and analyzed by using SPSS version 20. The descriptive data were summarized in percentages, median, and IQR. Logistic regression was analyzed to determine associated factors. To say the data were statistically significant, the
resultsA total of 81 study participants were included. Of them, 56.8% (46/81) and 67.9% (55/81) were female and urban residents, respectively. The prevalence of hepatitis co-infection was 21% (95% CI: 17%, 23%). Further, the prevalence of HBV/HIV and HCV/HIV was 13.5% (95% CI: 10.5%, 16.5%) and 8.6% (95% CI: 5.6%, 11.6%), respectively. Wise use of highly active antiretroviral therapy (HAART) 0.01 (0.00, 0.213) was a preventive factor to hepatitis infection. CONCLUSION AND RECOMMENDATION: The HBV and HCV co-infection among HIV-positive patients was a significant public health concern. Also, having wise use of HAART can reduce exposure to hepatitis co-infection. Therefore, clear strategies on hepatitis screening and wise use of HAART to HIV would be critical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.